---
title: "Ipilimumab"
slug: "ipilimumab"
date: "2024-01-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Overview-immunotherapy and cellular therapy]]

# Ipilimumab

- Mechanism:
  - Binds to CTLA-4
- Dosing:
  - 3 mg/kg IV every 3 wks (up to 4 doses);
  - tx can be held due to â†‘ liver enzymes
- PK/PD: T1/2 âˆ¼15 d
- AEs:
  - Musculoskeletal pain,
  - fatigue,
  - rash,
  - diarrhea,
  - & immune-mediated AEs (BBW,
  - commonly includes dermatitis,
  - endocrine disorders,
  - enterocolitis,
  - hepatitis)
- DDI: No significant drug interactions
- Clinical pearls: Tx immune-related tox w/ steroids (prednisone 1-2 mg/kg/d)
